High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- Kardigan Inc. shares rose iver 27% roughly one hour into its Nasdaq debut on Thursday, after the heart-health focused biotech raised $400 million in an initial public offering.
With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds. Bristol Myers Squibb (NYSE:BMY) offers a 4.39% yield backed by 94 consecutive years of dividend payments. The pharma giant is rebuilding around a Growth Portfolio (Eliquis, Camzyos, Breyanzi) while legacy drugs face generic erosion. ... A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline.
As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX.
BioArctic AB (BRCTF) reports robust financial performance and advances in Alzheimer's treatment, while navigating market access hurdles and rising operational costs.
Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines. • Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its use in research, drug development, manufacturing and other commercial and medical affairs. • Agentic AI, which requires little human intervention, could increase clinical development productivity by about 35% to 45% over the next five years, consultancy McKinsey said last year.
The deal helps solidify Anthropic’s commitment to the life sciences sector as it targets more enterprise clients.
Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.
Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
Find insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.
U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.